Search

Your search keyword '"Aya Kitaoka"' showing total 3 results
Start Over Author "Aya Kitaoka" Topic rc254-282
3 results on '"Aya Kitaoka"'

1. Acute development of fatal myocarditis after pembrolizumab in non-small-cell lung cancer with thymoma

Author

Aya Kitaoka, Kazuya Tanimura, Yuto Yasuda, Kensuke Nishioka, Yutaka Hirayama, Kiyoshi Uemasu, Daisuke Iwashima, Takashi Uegaito, Mitsuo Matsuda, Emi Date, Norishige Iizuka, and Ken-ichi Takahashi

Subjects
Pembrolizumab, Myocarditis, Non-small-cell lung cancer, Thymoma, irAE, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

We herein report the case of a sixty-four-year-old woman with stage IV lung adenocarcinoma with thymoma. The adenocarcinoma showed 95% tumor proportion scores of PD-L1 (Programmed death-ligand 1) expression without driver mutations. She was treated with pembrolizumab as 1st-line chemotherapy. Creatine kinase elevation was observed on the 15th day, and fatal myocarditis developed on the 20th day despite steroid therapy. The autopsy showed lymphocyte-infiltrated cardiac muscle, and pembrolizumab-induced myocarditis was diagnosed.Our case indicates that lung cancer combined with thymoma should alert clinicians to monitor the early onset of myocarditis in patients on immune checkpoint inhibitor therapy.

Published
2021
Full Text
View/download PDF

2. Anti-SOX1 antibody-positive paraneoplastic neurological syndrome presenting with paraneoplastic encephalomyelitis caused by small-cell lung cancer: A case report

Author

Kenichi Iwasa, Kiyoshi Uemasu, Yutaka Hirayama, Aya Kitaoka, Yuto Yasuda, Daisuke Iwashima, Satoru Tada, and Ken-ichi Takahashi

Subjects
Anti-SOX1 antibody, Paraneoplastic neurological syndromes, Small-cell lung cancer, Steroid therapy, Abbreviations, Anti-Sry-like high-mobility group box 1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2021
Full Text
View/download PDF

3. Acute development of fatal myocarditis after pembrolizumab in non-small-cell lung cancer with thymoma

Author

Kiyoshi Uemasu, Mitsuo Matsuda, Norishige Iizuka, Ken-ichi Takahashi, Emi Date, Yuto Yasuda, Kensuke Nishioka, Daisuke Iwashima, Kazuya Tanimura, Yutaka Hirayama, Aya Kitaoka, and Takashi Uegaito

Subjects
medicine.medical_specialty, Thymoma, Myocarditis, medicine.medical_treatment, Pembrolizumab, Gastroenterology, irAE, Internal medicine, medicine, Lung cancer, RC254-282, General Environmental Science, Chemotherapy, Lung, biology, business.industry, General Engineering, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, medicine.anatomical_structure, biology.protein, General Earth and Planetary Sciences, Adenocarcinoma, Creatine kinase, business, Non-small-cell lung cancer
Abstract

We herein report the case of a sixty-four-year-old woman with stage IV lung adenocarcinoma with thymoma. The adenocarcinoma showed 95% tumor proportion scores of PD-L1 (Programmed death-ligand 1) expression without driver mutations. She was treated with pembrolizumab as 1st-line chemotherapy. Creatine kinase elevation was observed on the 15th day, and fatal myocarditis developed on the 20th day despite steroid therapy. The autopsy showed lymphocyte-infiltrated cardiac muscle, and pembrolizumab-induced myocarditis was diagnosed. Our case indicates that lung cancer combined with thymoma should alert clinicians to monitor the early onset of myocarditis in patients on immune checkpoint inhibitor therapy.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results